Canlyniadau Chwilio - James Barsoum

  • Dangos 1 - 13 canlyniadau o 13
Mireinio'r Canlyniadau
  1. 1
    Preferential localization of variant nucleosomes near the 5'-end of the mouse dihydrofolate reductase gene.

    Preferential localization of variant nucleosomes near the 5'-end of the mouse dihydrofolate reductase gene. gan James Barsoum, Alexander Varshavsky

    Cyhoeddwyd 1985
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  2. 2
    Tat-mediated delivery of heterologous proteins into cells.

    Tat-mediated delivery of heterologous proteins into cells. gan Stephen E. Fawell, J Seery, Yasmin Daikh, Carol Moore, L L Chen, Blake Pepinsky, James Barsoum

    Cyhoeddwyd 1994
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  3. 3
    Sequestration of Adenoviral Vector by Kupffer Cells Leads to a Nonlinear Dose Response of Transduction in Liver

    Sequestration of Adenoviral Vector by Kupffer Cells Leads to a Nonlinear Dose Response of Transduction in Liver gan Nianjun Tao, Guangping Gao, Michael Parr, Julie Johnston, Timothy Baradet, James M. Wilson, James Barsoum, Stephen E. Fawell

    Cyhoeddwyd 2001
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  4. 4
    The novel HSP90 inhibitor STA-9090 exhibits activity against Kit-dependent and -independent malignant mast cell tumors

    The novel HSP90 inhibitor STA-9090 exhibits activity against Kit-dependent and -independent malignant mast cell tumors gan Tzu‐yin Lin, Misty D. Bear, Zhenjian Du, Kevin P. Foley, Weiwen Ying, James Barsoum, Cheryl A. London

    Cyhoeddwyd 2008
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  5. 5
    Phase I Evaluation of STA-1474, a Prodrug of the Novel HSP90 Inhibitor Ganetespib, in Dogs with Spontaneous Cancer

    Phase I Evaluation of STA-1474, a Prodrug of the Novel HSP90 Inhibitor Ganetespib, in Dogs with Spontaneous Cancer gan Cheryl A. London, Misty D. Bear, Jennifer McCleese, Kevin P. Foley, Reji Paalangara, Takayo Inoue, Weiwen Ying, James Barsoum

    Cyhoeddwyd 2011
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  6. 6
    Elesclomol induces cancer cell apoptosis through oxidative stress

    Elesclomol induces cancer cell apoptosis through oxidative stress gan Jessica R. Kirshner, Suqin He, Vishwasenani Balasubramanyam, Jane Kepros, Chin‐Yu Yang, Mei Zhang, Zhenjian Du, James Barsoum, John Bertin

    Cyhoeddwyd 2008
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  7. 7
    Interferon-β gene therapy inhibits tumor formation and causes regression of established tumors in immune-deficient mice

    Interferon-β gene therapy inhibits tumor formation and causes regression of established tumors in immune-deficient mice gan Xiao-Qiang Qin, Nianjun Tao, Amie Dergay, Pamela Moy, Stephen E. Fawell, Alan R. Davis, James M. Wilson, James Barsoum

    Cyhoeddwyd 1998
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  8. 8
    Apilimod Inhibits the Production of IL-12 and IL-23 and Reduces Dendritic Cell Infiltration in Psoriasis

    Apilimod Inhibits the Production of IL-12 and IL-23 and Reduces Dendritic Cell Infiltration in Psoriasis gan Yumiko Wada, Irma Cardinale, Artemis Khatcherian, John Man Tak Chu, Aaron B. Kantor, Alice B. Gottlieb, Noriaki Tatsuta, Eric Jacobson, James Barsoum, James G. Krueger

    Cyhoeddwyd 2012
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  9. 9
    Selective abrogation of Th1 response by STA-5326, a potent IL-12/IL-23 inhibitor

    Selective abrogation of Th1 response by STA-5326, a potent IL-12/IL-23 inhibitor gan Yumiko Wada, Rongzhen Lu, Dan Zhou, John Man Tak Chu, Teresa Przewloka, Shijie Zhang, Long Li, Yaming Wu, June Qin, Vishwasenani Balasubramanyam, James Barsoum, Mitsunori Ono

    Cyhoeddwyd 2006
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  10. 10
    Multifaceted Intervention by the Hsp90 Inhibitor Ganetespib (STA-9090) in Cancer Cells with Activated JAK/STAT Signaling

    Multifaceted Intervention by the Hsp90 Inhibitor Ganetespib (STA-9090) in Cancer Cells with Activated JAK/STAT Signaling gan David A. Proia, Kevin P. Foley, Tim Korbut, Jim Sang, Don Smith, Richard C. Bates, Yuan Liu, Alex Rosenberg, Dan Zhou, Keizo Koya, James Barsoum, Ronald K. Blackman

    Cyhoeddwyd 2011
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  11. 11
    Ganetespib, a Unique Triazolone-Containing Hsp90 Inhibitor, Exhibits Potent Antitumor Activity and a Superior Safety Profile for Cancer Therapy

    Ganetespib, a Unique Triazolone-Containing Hsp90 Inhibitor, Exhibits Potent Antitumor Activity and a Superior Safety Profile for Cancer Therapy gan Weiwen Ying, Zhenjian Du, Lijun Sun, Kevin P. Foley, David A. Proia, Ronald K. Blackman, Dan Zhou, Takayo Inoue, Noriaki Tatsuta, Jim Sang, Shuxia Ye, Jamie Acquaviva, Luisa Shin Ogawa, Yumiko Wada, James Barsoum, Keizo Koya

    Cyhoeddwyd 2011
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  12. 12
    Gene activation of SMN by selective disruption of lncRNA-mediated recruitment of PRC2 for the treatment of spinal muscular atrophy

    Gene activation of SMN by selective disruption of lncRNA-mediated recruitment of PRC2 for the treatment of spinal muscular atrophy gan Caroline J. Woo, Verena Maier, Roshni Davey, James F. Brennan, Guangde Li, John Brothers, Brian E. Schwartz, Susana Gordo, Anne Kasper, Trevor R. Okamoto, Hans Johansson, Berhan Mandefro, Dhruv Sareen, Peter Bialek, B. Nelson Chau, Balkrishen Bhat, David A. Bullough, James Barsoum

    Cyhoeddwyd 2017
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  13. 13
    Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in <i>In Vitro</i> and <i>In Vivo</i> Models of Non–Small Cell Lung Cancer

    Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in <i>In Vitro</i> and <i>In Vivo</i> Models of Non–Small Cell Lung Cancer gan Takeshi Shimamura, Samanthi A. Perera, Kevin P. Foley, Jim Sang, Scott J. Rodig, Takayo Inoue, Liang Chen, Danan Li, Julián Carretero, Yuchen Li, Papiya Sinha, Christopher D. Carey, Christa L. Borgman, John-Paul Jimenez, Matthew Meyerson, Weiwen Ying, James Barsoum, Kwok‐Kin Wong, Geoffrey I. Shapiro

    Cyhoeddwyd 2012
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:

Offerynnau Chwilio: